The first patient infusion and the start of a clinical investigation of JWATM214 in people with advanced hepatocellular carcinoma (HCC) were both reported by JW Therapeutics, an independent and creative biotechnology business.
Primary hepatic carcinoma is a common malignant tumour of the gastrointestinal tract that has a poor prognosis for the liver. HCC makes up 85% to 90% of primary liver cancers and is the most frequent pathological form. With 466,000 new cases and 422,000 fatalities from primary liver cancer each year, China has the highest incidence and fatality rates in the world. Patients receive only little benefits from existing treatments because the median progression-free survival of patients following first- and second-line therapy is only about 6 months. Thus, it is urgently necessary to create a successful therapy for individuals with advanced HCC that is recurring and metastatic.
In this JWATM214 first-in-human study, adult patients with advanced HCC that expresses GPC-3 will have their safety and tolerability assessed, the recommended phase 2 dose (RP2D) will be determined, the drug’s pharmacokinetic profile will be examined, and preliminary efficacy results will be reported.
Glypican-3 (GPC-3) has emerged as a target for the detection and management of HCC due to its overexpression in a variety of malignant tumours, including HCC. It has been initially shown and reported that T-cell immunotherapy targeting GPC-3 is a viable option for the treatment of HCC patients. Based on the ARTEMIS platform of Eureka and Lyell’s T cell anti-exhaustion technology, JW Therapeutics independently developed JWATM214, an autologous T-cell immunotherapy candidate medication that targets GPC-3. For more long-lasting and superior anti-tumor activity, it combines the high affinity and specificity of the GPC-3 monoclonal antibody with the addition of cJun protein regulation based on JWATM204 to postpone T cell exhaustion, potentially offering a novel treatment for patients with advanced HCC who express GPC-3.
In 2020, JW Therapeutics entered into agreements with Eureka and Lyell and obtained the rights to use Lyell’s T cell anti-exhaustion technology and Eureka’s ARTEMIS technology for the development, production, and sale of products in China (including the Chinese mainland, Hong Kong, Macao, and Taiwan) and the ASEAN member states.
Based on the ARTEMIS platform of Eureka and Lyell’s T cell anti-exhaustion technology, JW Therapeutics independently developed JWATM214, an autologous T-cell immunotherapy candidate medication that targets GPC-3. For more long-lasting and superior anti-tumor activity, it combines the high affinity and specificity of the GPC-3 monoclonal antibody with the addition of cJun protein regulation based on JWATM204 to postpone T cell exhaustion, potentially offering a novel treatment for patients with advanced HCC who express GPC-3.
With a focus on creating, producing, and selling cell immunotherapy treatments, JW Therapeutics is an independent, cutting-edge biotechnology firm that is dedicated to setting the standard for innovation in the field.
